J&J makes new in­vest­ments in mi­cro­bio­me R&D; UK’s Ar­ix out to raise £100 mil­lion for new biotech in­vest­ments

• J&J is mak­ing some new in­vest­ments in mi­cro­bio­me re­search, in­clud­ing adding Caelus Health to its J&J In­no­va­tion port­fo­lio. “These col­lab­o­ra­tions and in­vest­ments will cre­ate crit­i­cal new in­sights to ad­dress meta­bol­ic dis­or­ders through mi­cro­bio­me-based di­ag­nos­tics and ther­a­peu­tics,” said Dirk Gev­ers, PhD, Glob­al Head, Janssen Hu­man Mi­cro­bio­me In­sti­tute. “By part­ner­ing with en­tre­pre­neurs, biotechs and aca­d­e­mics and bring­ing in­no­v­a­tive op­por­tu­ni­ties to­geth­er with our ex­per­tise, we look to move mi­cro­bio­me sci­ence for­ward and de­liv­er fu­ture so­lu­tions that pro­mote in­di­vid­ual health.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER